Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
The notes were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of common stock issuable upon conversion of the notes, if any, have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold in
This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes or any other securities, nor shall there be any offer, solicitation or sale of the notes or any other securities (including the shares of Karyopharm’s common stock issuable upon conversion of the notes, if any) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm's current expectations due to risks and uncertainties inherent in Karyopharm’s business, including, without limitation, risks and uncertainties associated with market conditions. The failure to meet expectations with respect to any of the foregoing matters may reduce Karyopharm's stock price. These and other risks are described under the caption “Risk Factors” in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended
Vice President, Investor and Public Relations
857-297-2241 | email@example.com
Source: Karyopharm Therapeutics Inc.